44th NANOS Annual Meeting, Hawaii, The Big Island, US

GenSight Biologics will participate to the 2018 North American Neuro-Ophthalmology Society (NANOS) 44th Annual Meeting at the Hilton Waikoloa Village on The Big Island of Hawaii. Three abstracts, related to its lead product candidate GS010 to treat LHON, are accepted for one oral and two poster presentations.  

Phase I/II Clinical Trial Data after 96 Weeks of Follow-up

“Safety/Acuity Outcomes 96-Weeks Post-Treatment with rAAV2/2-ND4; Gene Therapy for ND4 LHON: a Phase I/II Trial”will be presented by Dr. Barrett Katz, MD, MBA, Chief Medical Officer, GenSight Biologics, New York, US.

  • Oral Presentation
  • Scientific Platform Session I, Monarchy Ballroom
  • Monday, March 5, 2018, 5:30-5:45 pm

RESCUE and REVERSE Phase III Clinical Trials Baseline Characteristics and OCT Findings

“Baseline Characteristics of LHON Subjects in the RESCUE and REVERSE Phase III Gene Therapy Trials”will be presented by Dr. Mark Moster, MD, Neuro-Ophthalmology Service, Wills Eye Hospital, Departments of Neurology and Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia (PA), US.

  • Poster Presentation
  • Poster Session II: Scientific Advancements in Neuro-Ophthalmology
  • Poster #161
  • Tuesday, March 6, 2018, 6:00-9:30 pm

“Baseline OCT Findings in Phase 3 RESCUE and REVERSE Trials”will be presented by Dr. Robert C. Sergott, MD, Neuro-Ophthalmology Service, Wills Eye Hospital, Thomas Jefferson University and Optic Nerve Research Center, Philadelphia (PA), US.

  • Poster Presentation
  • Poster Session II: Scientific Advancements in Neuro-Ophthalmology
  • Poster #170
  • Tuesday, March 6, 2018, 6:00-9:30 pm